Royalty Pharma plc (RPRX) Stock Analysis

Q: What is the RPRX stock price target?

Take-profit $49.46 (-1.3% upside). Prior stop was $48.31.

Q: What are the risks of investing in RPRX?

Analyst target reached - limited upside remaining; Near 52-week high (0.3% away); Earnings in 6 days (event risk); Target reached (-8.9% upside); Momentum score 3.8/10 — below 4.5 minimum.

Q: Is RPRX overvalued or undervalued?

Royalty Pharma plc trades at a P/E of 27.8 (forward 9.0). TrendMatrix value score: 4.3/10. Overall verdict: Sell.

Q: What do analysts say about RPRX?

16 analysts cover RPRX with a consensus score of 4.2/5. Average price target: $52.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

$50.13-1.3% A.UpsideScore 4.6/10#121 of 158 Biotechnology

Stop $48.31Target $49.46(resistance)A.R:R -1.3:1

Analyst target$52.44+4.6%9 analysts

$49.46our TP

$50.13price

$52.44mean

$46

$63

Sell if holding. Analyst target reached at $50.13 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.3% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.

Thesis

Rewards

Strong earnings beat streak (3/4)

Risks

Analyst target reached - limited upside remaining

Near 52-week high (0.3% away)

Earnings in 6 days (event risk)

Key Metrics

P/E (TTM)27.8

P/E (Fwd)9.0

Mkt Cap$29.3B

EV/EBITDA21.0

Profit Mgn32.4%

ROE13.2%

Rev Growth4.8%

Beta0.39

Dividend1.90%

Rating analysts16

Quality Signals

Piotroski F8/9

Options Flow

P/C1.21bearish

IV43%normal

Max Pain$40-20.2% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value4.315%0.64

Quality5.915%0.89

Growth3.815%0.57

Momentum3.810%0.38

Sentiment6.010%0.60

Insider Activity3.810%0.38

Peer Rank3.810%0.38

Technical Setup4.25%0.21

Risk Profile6.75%0.34

Catalyst5.35%0.27

Overall (Σ contributions)4.65

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth

3.7

Earnings Growth

3.8

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.9

Obv

1.0

Macd

3.5

Rsi

4.5

Ma Position

9.0

Overbought (RSI 71)Volume distribution (falling OBV)Above 200-day MA

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

3.0

Value Rank

4.0

Quality Rank

8.3

Superior ROE vs peersBest-in-class margins

GatesMomentum 3.8<4.5A.R:R -1.2=NEGATIVEEARNINGS PROXIMITY 6d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Moderate

RSI

71 · Overbought

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $46.53Resistance $50.47

Price Targets

$48

$49

A.Upside-1.3%

A.R:R-1.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Target reached (-8.9% upside)

! Momentum score 3.8/10 — below 4.5 minimum

! Negative risk/reward — downside exceeds upside

Earnings

3/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is RPRX stock a buy right now?

Sell if holding. Analyst target reached at $50.13 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.3% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $48.31. Score 4.6/10, moderate confidence.

What is the RPRX stock price target?

Take-profit target: $49.46 (-1.3% upside). Prior stop was $48.31. Stop-loss: $48.31.

What are the risks of investing in RPRX?

Analyst target reached - limited upside remaining; Near 52-week high (0.3% away); Earnings in 6 days (event risk).

Is RPRX overvalued or undervalued?

Royalty Pharma plc trades at a P/E of 27.8 (forward 9.0). TrendMatrix value score: 4.3/10. Verdict: Sell.

What do analysts say about RPRX?

16 analysts cover RPRX with a consensus score of 4.2/5. Average price target: $52.

What does Royalty Pharma plc do?Royalty Pharma is the largest buyer of biopharmaceutical royalties, with a portfolio of royalties on 35+ commercial...

Royalty Pharma is the largest buyer of biopharmaceutical royalties, with a portfolio of royalties on 35+ commercial products including Vertex Trikafta/Alyftrek, GSK Trelegy, Biogen Tysabri/Spinraza, AbbVie/J&J Imbruvica, and 20 development-stage product candidates. Portfolio Receipts of $3.3 billion in 2025 come from royalties on licensee product sales; Capital Deployment of $2.6 billion was made and $4.7 billion in new transactions announced. As of December 31, 2025, total debt principal was $9.2 billion.